- Home
- FFA vs ERAS Comparison
FFA vs ERAS Comparison
Compare FFA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- ERAS
- Stock Information
- Founded
- FFA 2004
- ERAS 2018
- Country
- FFA United States
- ERAS United States
- Employees
- FFA N/A
- ERAS N/A
- Industry
- FFA Investment Managers
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- FFA Finance
- ERAS Health Care
- Exchange
- FFA Nasdaq
- ERAS Nasdaq
- Market Cap
- FFA 416.1M
- ERAS 439.7M
- IPO Year
- FFA N/A
- ERAS 2021
- Fundamental
- Price
- FFA $21.41
- ERAS $2.92
- Analyst Decision
- FFA
- ERAS Buy
- Analyst Count
- FFA 0
- ERAS 6
- Target Price
- FFA N/A
- ERAS $3.50
- AVG Volume (30 Days)
- FFA 26.1K
- ERAS 1.4M
- Earning Date
- FFA 01-01-0001
- ERAS 11-12-2025
- Dividend Yield
- FFA 6.72%
- ERAS N/A
- EPS Growth
- FFA N/A
- ERAS N/A
- EPS
- FFA N/A
- ERAS N/A
- Revenue
- FFA N/A
- ERAS N/A
- Revenue This Year
- FFA N/A
- ERAS N/A
- Revenue Next Year
- FFA N/A
- ERAS N/A
- P/E Ratio
- FFA N/A
- ERAS N/A
- Revenue Growth
- FFA N/A
- ERAS N/A
- 52 Week Low
- FFA $15.84
- ERAS $1.01
- 52 Week High
- FFA $19.30
- ERAS $3.30
- Technical
- Relative Strength Index (RSI)
- FFA 49.35
- ERAS 67.09
- Support Level
- FFA $20.85
- ERAS $2.75
- Resistance Level
- FFA $21.54
- ERAS $3.08
- Average True Range (ATR)
- FFA 0.31
- ERAS 0.21
- MACD
- FFA -0.06
- ERAS 0.04
- Stochastic Oscillator
- FFA 55.39
- ERAS 82.99
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.